% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • ajthedrifter ajthedrifter Mar 21, 2012 5:20 PM Flag

    imuc and gale

    1. efficacy of phase 1 trial data---small sample but results can't be ignored

    2. patent protection on ICT-107 their lead candidate

    3. licensing agreements in place to further develop pipeline

    4. strong cash position and low burn rate ----see the recent sec filing to verify this

    5. manufacturing process allows them to produce their compound at a relatively low cost per dose, which will translate to higher profit margins compared to peers